文献速递复苏、休克与脓毒症消化、代谢与肾脏急症重症综合管理与镇静镇痛

阿奇霉素与脓毒症相关急性肾损伤危重患者的主要不良肾脏事件

Azithromycin and Major Adverse Kidney Events in Critically Ill Patients With Sepsis-Associated Acute Kidney Injury.
PubMed 文献 · Shock · 2022-01-01
一句话结论单中心回顾性队列提示,SA-AKI 患者入院48小时内接受阿奇霉素与出院时MAKE odds降低独立相关(aOR 0.62)。

该单中心回顾性队列纳入737例脓毒症相关急性肾损伤(SA-AKI)危重成人,152例(20.6%)在入院48小时内接受至少一剂阿奇霉素。主要终点为出院时主要不良肾脏事件(MAKE,死亡、需肾脏替代治疗或eGFR下降≥25%的复合终点)。早期阿奇霉素组MAKE发生率38.8%,未接受组48.4%(P=0.035);多因素logistic回归显示阿奇霉素与MAKE odds降低独立相关(aOR 0.62,95%CI 0.41-0.93)。结论为早期阿奇霉素暴露与出院时MAKE odds降低独立相关,但为回顾性单中心设计,不能确立因果。

要点

  • SA-AKI危重成人中,入院48小时内接受≥1剂阿奇霉素者出院时MAKE为38.8%,未接受者为48.4%(P=0.035)。
  • 多因素logistic回归校正混杂后,阿奇霉素与出院时MAKE odds降低独立相关(aOR 0.62,95%CI 0.41-0.93)。
  • MAKE复合终点包括死亡、需要肾脏替代治疗、eGFR下降≥25%,于出院时评估。
  • 研究为单中心回顾性队列(737例,152例接受阿奇霉素),仅提示关联,不能据此在床旁常规加用阿奇霉素。
  • 原文未提及阿奇霉素剂量、给药途径、频次或疗程,也未报告关键次要终点与不良事件。

适用人群与场景

  • 单中心回顾性队列纳入的危重成人脓毒症相关急性肾损伤(SA-AKI)患者,共737例,其中152例(20.6%)接受早期阿奇霉素。
  • 原文未提及具体纳入标准、排除标准、ICU类型或病情阶段。

诊断标准与关键阈值

  • 早期阿奇霉素暴露定义为:因SA-AKI入院后48小时内接受一剂或多剂阿奇霉素。
  • 主要终点MAKE为出院时评估的复合终点:死亡、需要肾脏替代治疗、或估算肾小球滤过率(eGFR)下降25%或以上。

处置流程与药物剂量

  • 原文未提及阿奇霉素的具体剂量、单位、给药途径、频次或疗程。
  • 原文未提及SA-AKI的其他处置流程或药物方案。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:单中心、回顾性队列研究;样本量737例SA-AKI危重成人,单中心。
  • 暴露与对照:早期阿奇霉素暴露(入院48小时内≥1剂,152例,20.6%)对比未接受阿奇霉素者。
  • 主要终点:出院时MAKE发生率38.8% vs 48.4%(P=0.035)。
  • 多因素logistic回归:阿奇霉素与出院时MAKE odds降低独立相关(aOR 0.62,95%CI 0.41-0.93)。

证据类型、等级与局限

  • 证据类型:单中心、回顾性队列研究。
  • 局限:单中心、回顾性设计,存在残余混杂可能;仅显示关联,不能推断因果;原文未提及剂量信息。

对床旁实践的改变

  • 该研究提示SA-AKI患者早期阿奇霉素暴露与出院时MAKE odds降低相关,但因系单中心回顾性队列,不能据此在抢救室或ICU常规加用阿奇霉素。
  • 原文未提供剂量、疗程及适用/不适用人群信息,床旁决策不能直接套用该关联结果。
  • 常见陷阱:将回顾性关联误读为因果或治疗推荐;原文未报告不良事件,不能据此评估用药安全性。

指南或共识出处

  • 原文未提及指南或共识出处;文献发表于Shock。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Sepsis-associated acute kidney injury (SA-AKI) is associated with significant morbidity and mortality. Immune dysregulation is a hallmark of sepsis, with important contributions to organ dysfunction including injury and repair mechanisms in AKI. Macrolide antibiotics, such as azithromycin, have previously demonstrated in preclinical models a myriad of immunomodulatory effects that may benefit critically ill patients with SA-AKI. The aim of this study was to determine if early receipt of azithromycin in SA-AKI is associated with a reduction in major adverse kidney events (MAKE) at hospital discharge.

METHODS: This was a single center, retrospective cohort study of critically ill adult patients with SA-AKI. Early exposure to azithromycin was defined as receipt of one or more doses within 48 h of a hospital admission with SA-AKI. The primary outcome of MAKE assessed at hospital discharge was the composite of death, requirement for kidney replacement therapy, or a decline in estimated glomerular filtration rate of 25% or more. Multivariable logistic regression was used to account for potential confounders in the assessment.

RESULTS: Of 737 included patients with SA-AKI, 152 (20.6%) received azithromycin. Patients that received early azithromycin were less likely to experience MAKE at hospital discharge when compared to those patients not receiving azithromycin: 38.8% versus 48.4% (P = 0.035). In multivariable logistic regression, receipt of azithromycin was independently associated with a decreased odds of MAKE at hospital discharge (aOR 0.62, 95% CI 0.41-0.93).

CONCLUSIONS: Early exposure to azithromycin in SA-AKI is independently associated with lower odds of MAKE at hospital discharge.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Behal, Nguyen, Li, et al. Azithromycin and Major Adverse Kidney Events in Critically Ill Patients With Sepsis-Associated Acute Kidney Injury. Shock. 2022. PMID: 34731096. doi:10.1097/SHK.0000000000001883

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。